{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T10:27:53Z","timestamp":1784370473896,"version":"3.55.0"},"reference-count":139,"publisher":"MDPI AG","issue":"20","license":[{"start":{"date-parts":[[2021,10,14]],"date-time":"2021-10-14T00:00:00Z","timestamp":1634169600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01-DA042157"],"award-info":[{"award-number":["R01-DA042157"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01-DA003672"],"award-info":[{"award-number":["R01-DA003672"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01-DA040460"],"award-info":[{"award-number":["R01-DA040460"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R03-DA031988"],"award-info":[{"award-number":["R03-DA031988"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005289","name":"National Institute of Justice","doi-asserted-by":"publisher","award":["2012-R2-CX-K001"],"award-info":[{"award-number":["2012-R2-CX-K001"]}],"id":[{"id":"10.13039\/100005289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000074","name":"U.S. Department of Justice","doi-asserted-by":"publisher","award":["DJD-14-HQ-P-0713"],"award-info":[{"award-number":["DJD-14-HQ-P-0713"]}],"id":[{"id":"10.13039\/100000074","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.mdpi.com"],"crossmark-restriction":true},"short-container-title":["Molecules"],"abstract":"<jats:p>The Sterling Research Group identified pravadoline as an aminoalkylindole (AAI) non-steroidal anti-inflammatory pain reliever. As drug design progressed, the ability of AAI analogs to block prostaglandin synthesis diminished, and antinociceptive activity was found to result from action at the CB1 cannabinoid receptor, a G-protein-coupled receptor (GPCR) abundant in the brain. Several laboratories applied computational chemistry methods to ultimately conclude that AAI and cannabinoid ligands could overlap within a common binding pocket but that WIN55212-2 primarily utilized steric interactions via aromatic stacking, whereas cannabinoid ligands required some electrostatic interactions, particularly involving the CB1 helix-3 lysine. The Huffman laboratory identified strategies to establish CB2 receptor selectivity among cannabimimetic indoles to avoid their CB1-related adverse effects, thereby stimulating preclinical studies to explore their use as anti-hyperalgesic and anti-allodynic pharmacotherapies. Some AAI analogs activate novel GPCRs referred to as \u201cAlkyl Indole\u201d receptors, and some AAI analogs act at the colchicine-binding site on microtubules. The AAI compounds having the greatest potency to interact with the CB1 receptor have found their way into the market as \u201cSpice\u201d or \u201cK2\u201d. The sale of these alleged \u201cherbal products\u201d evades FDA consumer protections for proper labeling and safety as a medicine, as well as DEA scheduling as compounds having no currently accepted medical use and a high potential for abuse. The distribution to the public of potent alkyl indole synthetic cannabimimetic chemicals without regard for consumer safety contrasts with the adherence to regulatory requirements for demonstration of safety that are routinely observed by ethical pharmaceutical companies that market medicines.<\/jats:p>","DOI":"10.3390\/molecules26206190","type":"journal-article","created":{"date-parts":[[2021,10,14]],"date-time":"2021-10-14T22:42:18Z","timestamp":1634251338000},"page":"6190","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["The Spicy Story of Cannabimimetic Indoles"],"prefix":"10.3390","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2810-0164","authenticated-orcid":false,"given":"Allyn","family":"Howlett","sequence":"first","affiliation":[{"name":"Department of Physiology and Pharmacology, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0097-4804","authenticated-orcid":false,"given":"Brian","family":"Thomas","sequence":"additional","affiliation":[{"name":"Department of Analytical Sciences, The Cronos Group, Toronto, ON M5V 2H1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0289-2252","authenticated-orcid":false,"given":"John","family":"Huffman","sequence":"additional","affiliation":[{"name":"Department of Chemistry, Clemson University, Clemson, SC 29634, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,10,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1016\/0024-3205(84)90278-9","article-title":"Inhibition of neuroblastoma adenylate cyclase by cannabinoid and nantradol compounds","volume":"35","author":"Howlett","year":"1984","journal-title":"Life Sci."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/S0026-895X(25)15066-9","article-title":"Cannabinoid inhibition of adenylate cyclase. Pharmacology of the response in neuroblastoma cell membranes","volume":"26","author":"Howlett","year":"1984","journal-title":"Mol. Pharmacol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"367s","DOI":"10.1002\/j.1552-4604.1981.tb02616.x","article-title":"Levonantradol: A role for central prostanoid mechanisms?","volume":"21","author":"Milne","year":"1981","journal-title":"J. Clin. Pharmacol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"271S","DOI":"10.1002\/j.1552-4604.1981.tb02605.x","article-title":"Selective and Potent Analgetics Derived from Cannabinoids","volume":"21","author":"Johnson","year":"1981","journal-title":"J. Clin. Pharmacol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"320S","DOI":"10.1002\/j.1552-4604.1981.tb02610.x","article-title":"Evaluation of Intramuscular Levonantradol and Placebo in Acute Postoperative Pain","volume":"21","author":"Jain","year":"1981","journal-title":"J. Clin. Pharmacol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"43S","DOI":"10.1002\/j.1552-4604.1981.tb02572.x","article-title":"Antiemetic Effect of Intramuscular Levonantradol in Patients Receiving Anticancer Chemotherapy","volume":"21","author":"Cronin","year":"1981","journal-title":"J. Clin. Pharmacol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"51S","DOI":"10.1002\/j.1552-4604.1981.tb02573.x","article-title":"Levonantradol for Chemotherapy-Induced Emesis: Phase I-II Oral Administration","volume":"21","author":"Laszlo","year":"1981","journal-title":"J. Clin. Pharmacol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/j.1552-4604.1984.tb01824.x","article-title":"Double-Blind Multiple-Dose Crossover Study of the Antiemetic Effect of Intramuscular Levonantradol Compared to Prochlorperazine","volume":"24","author":"Sheidler","year":"1984","journal-title":"J. Clin. Pharmacol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1002\/j.1552-4604.1984.tb02756.x","article-title":"Dose Ranging Evaluation of the Antiemetic Efficacy and Toxicity of Intramuscular Levonantradol in Cancer Subjects with Chemotherapy-Induced Emesis","volume":"24","author":"Stambaugh","year":"1984","journal-title":"J. Clin. Pharmacol."},{"key":"ref_10","unstructured":"(1981). Special Issue: Overview on the Current Status of Therapeutic Opportunities in Cannabinoid Research. J. Clin. Pharmacol., 21, 1S\u2013494S."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0026-895X(25)12377-8","article-title":"Cannabinoid inhibition of adenylate cyclase. Biochemistry of the response in neuroblastoma cell membranes","volume":"27","author":"Howlett","year":"1985","journal-title":"Mol. Pharmacol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S0026-895X(25)13196-9","article-title":"Nonclassical cannabinoid analgetics inhibit adenylate cyclase: Development of a cannabinoid receptor model","volume":"33","author":"Howlett","year":"1988","journal-title":"Mol. Pharmacol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0026-895X(25)10219-8","article-title":"Involvement of Gi in the inhibition of adenylate cyclase by cannabimimetic drugs","volume":"29","author":"Howlett","year":"1986","journal-title":"Mol. Pharmacol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S0026-895X(25)09876-1","article-title":"Determination and characterization of a cannabinoid receptor in rat brain","volume":"34","author":"Devane","year":"1988","journal-title":"Mol. Pharmacol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/0166-2236(90)90124-S","article-title":"The cannabinoid receptor: Biochemical, anatomical and behavioral characterization","volume":"13","author":"Howlett","year":"1990","journal-title":"Trends Neurosci."},{"key":"ref_16","first-page":"100","article-title":"Classical and Nonclassical Cannabinoids: Mechanism of Action-Brain Binding","volume":"96","author":"Howlett","year":"1990","journal-title":"NIDA Res. Monogr."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S0022-3565(25)23103-2","article-title":"Pharmacology of pravadoline: A new analgesic agent","volume":"255","author":"Haubrich","year":"1990","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1021\/jm00107a034","article-title":"Antinociceptive (aminoalkyl)indoles","volume":"34","author":"Bell","year":"1991","journal-title":"J. Med. Chem."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1016\/S0022-3565(25)23062-2","article-title":"Pravadoline: Profile in isolated tissue preparations","volume":"255","author":"Ward","year":"1990","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/S0022-3565(25)24755-3","article-title":"Aminoalkylindoles: Actions on specific G-protein-linked receptors","volume":"257","author":"Pacheco","year":"1991","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1021\/jm00079a016","article-title":"Conformationally restrained analogues of pravadoline: Nanomolar potent, enantioselective, (aminoalkyl)indole agonists of the cannabinoid receptor","volume":"35","author":"Estep","year":"1992","journal-title":"J. Med. Chem."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/S0022-3565(25)10448-5","article-title":"Aminoalkylindole analogs: Cannabimimetic activity of a class of compounds structurally distinct from delta 9-tetrahydrocannabinol","volume":"263","author":"Compton","year":"1992","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_23","first-page":"425","article-title":"Aminoalkylindoles (AAIs): A new route to the cannabinoid receptor?","volume":"105","author":"Ward","year":"1990","journal-title":"NIDA Res. Monogr."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/S0022-3565(25)10152-3","article-title":"Aminoalkylindole binding in rat cerebellum: Selective displacement by natural and synthetic cannabinoids","volume":"264","author":"Kuster","year":"1993","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1021\/jm950932r","article-title":"(Aminoalkyl)indole Isothiocyanates as Potential Electrophilic Affinity Ligands for the Brain Cannabinoid Receptor","volume":"39","author":"Yamada","year":"1996","journal-title":"J. Med. Chem."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/0006-8993(92)90428-C","article-title":"Distribution of cannabinoid receptors in rat brain determined with aminoalkylindoles","volume":"575","author":"Jansen","year":"1992","journal-title":"Brain Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1124\/dmd.30.10.1077","article-title":"In Vitro Metabolism ofR(+)-[2,3-Dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo [1,2,3-de]1,4-benzoxazinyl]-(1-naphthalenyl) methanone mesylate, a Cannabinoid Receptor Agonist","volume":"30","author":"Zhang","year":"2002","journal-title":"Drug Metab. Dispos."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"22","DOI":"10.70359\/bhc2000v025p022","article-title":"The Life Cycle of Sterling Drug, Inc","volume":"25","author":"Collins","year":"2000","journal-title":"Bull. Hist. Chem."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"705","DOI":"10.2174\/0929867306666220401125055","article-title":"Cannabimimetic indoles, pyrroles and indenes","volume":"6","author":"Huffman","year":"1999","journal-title":"Curr. Med. Chem."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.2174\/0929867054020864","article-title":"Recent developments in the medicinal chemistry of cannabimimetic indoles, pyrroles and indenes","volume":"12","author":"Huffman","year":"2005","journal-title":"Curr. Med. Chem."},{"key":"ref_31","unstructured":"Parrill, A.L. (1999). Unified pharmacophoric model for cannabinoids and aminoalkylindoles derived from molecular superimpositioin of CB1 cannabinoid receptor agonists CP55244 and WIN55212-2. Rational Drug Design: Novel Methodology and Practical Applications, American Chemical Society."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"4521","DOI":"10.1021\/jm980305c","article-title":"Three-Dimensional Quantitative Structure\u2013Activity Relationship Study of the Cannabimimetic (Aminoalkyl)indoles Using Comparative Molecular Field Analysis","volume":"41","author":"Shim","year":"1998","journal-title":"J. Med. Chem."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"3094","DOI":"10.1021\/jm00016a013","article-title":"Aminoalkylindoles: Structure-Activity Relationships of Novel Cannabinoid Mimetics","volume":"38","author":"Eissenstat","year":"1995","journal-title":"J. Med. Chem."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/0960-894X(95)00560-G","article-title":"C-Attached aminoalkylindoles: Potent cannabinoid mimetics","volume":"6","author":"Eissenstat","year":"1996","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1021\/jm010267o","article-title":"Molecular Interaction of the Antagonist N-(Piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide with the CB1 Cannabinoid Receptor","volume":"45","author":"Shim","year":"2002","journal-title":"J. Med. Chem."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1016\/0024-3205(95)00177-8","article-title":"Common cannabimimetic pharmacophoric requirements between aminoalkyl indoles and classical cannabinoids","volume":"56","author":"Xiet","year":"1995","journal-title":"Life Sci."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"4021","DOI":"10.1021\/jm980592k","article-title":"High-resolution NMR and computer modeling studies of the cannabimimetic aminoalkylindole prototype WIN-55212-2","volume":"42","author":"Xie","year":"1999","journal-title":"J. Med. Chem."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0022-3565(24)37496-8","article-title":"Structure-activity relationships of indole- and pyrrole-derived cannabinoids","volume":"285","author":"Wiley","year":"1998","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S0960-894X(01)80155-4","article-title":"Design, Synthesis and Pharmacology of Cannabimimetic Indoles","volume":"4","author":"Huffman","year":"1994","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S0968-0896(99)00305-3","article-title":"Synthesis and pharmacology of a hybrid cannabinoid","volume":"8","author":"Huffman","year":"2000","journal-title":"Bioorg. Med. Chem."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"5177","DOI":"10.1021\/jm9801197","article-title":"The Bioactive Conformation of Aminoalkylindoles at the Cannabinoid CB1 and CB2 Receptors: Insights Gained from (E)- and (Z)-Naphthylidene Indenes","volume":"41","author":"Reggio","year":"1998","journal-title":"J. Med. Chem."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S0968-0896(02)00451-0","article-title":"3-Indolyl-1-naphthylmethanes: New cannabimimetic indoles provide evidence for aromatic stacking interactions with the CB1 cannabinoid receptor","volume":"11","author":"Huffman","year":"2003","journal-title":"Bioorg. Med. Chem."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/S0026-895X(25)09082-0","article-title":"A lysine residue of the cannabinoid receptor is critical for receptor recognition by several agonists but not WIN55212-2","volume":"49","author":"Song","year":"1996","journal-title":"Mol. Pharmacol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0022-3565(24)37469-5","article-title":"Mutation of a highly conserved aspartate residue in the second transmembrane domain of the cannabinoid receptors, CB1 and CB2, disrupts G-protein coupling","volume":"285","author":"Tao","year":"1998","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1016\/S0006-2952(02)01031-6","article-title":"A critical role for a tyrosine residue in the cannabinoid receptors for ligand recognition","volume":"63","author":"McAllister","year":"2002","journal-title":"Biochem. Pharmacol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/S0026-895X(24)12547-3","article-title":"The difference between the CB(1) and CB(2) cannabinoid receptors at position 5.46 is crucial for the selectivity of WIN55212-2 for CB(2)","volume":"56","author":"Song","year":"1999","journal-title":"Mol. Pharmacol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1021\/ci0504824","article-title":"WIN55212-2 Docking to the CB1 Cannabinoid Receptor and Multiple Pathways for Conformational Induction","volume":"46","author":"Shim","year":"2006","journal-title":"J. Chem. Inf. Model."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1021\/ci040040c","article-title":"Steric Trigger as a Mechanism for CB1 Cannabinoid Receptor Activation","volume":"44","author":"Shim","year":"2004","journal-title":"J. Chem. Inf. Comput. Sci."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/bip.10424","article-title":"Homology model of the CB1 cannabinoid receptor: Sites critical for nonclassical cannabinoid agonist interaction","volume":"71","author":"Shim","year":"2003","journal-title":"Biopolymers"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/sj.bjp.0707531","article-title":"Cannabinoid CB2 receptors: A therapeutic target for the treatment of inflammatory and neuropathic pain","volume":"153","author":"Guindon","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2174\/138955709787001785","article-title":"Cannabinoid Type 2 Receptor as a Target for Chronic-Pain","volume":"9","author":"Beltramo","year":"2009","journal-title":"Mini-Rev. Med. Chem."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.pnpbp.2011.12.001","article-title":"CB2: Therapeutic target-in-waiting","volume":"38","author":"Atwood","year":"2012","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"641","DOI":"10.2174\/1389557054368844","article-title":"CB2 receptor ligands","volume":"5","author":"Huffman","year":"2005","journal-title":"Mini-Rev. Med. Chem."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.2174\/1381612003399347","article-title":"The Search for Selective Ligands for the CB2 Receptor","volume":"6","author":"Huffman","year":"2000","journal-title":"Curr. Pharm. Des."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2174\/156802608783498014","article-title":"Recent Advances in the Development of Selective Ligands for the Cannabinoid CB2 Receptor","volume":"8","author":"Huffman","year":"2008","journal-title":"Curr. Top. Med. Chem."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S0026-895X(25)10492-6","article-title":"Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors","volume":"48","author":"Felder","year":"1995","journal-title":"Mol. Pharmacol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/S0022-3565(25)20744-3","article-title":"Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): Identification of cannabinoid receptor subtype selective ligands","volume":"278","author":"Showalter","year":"1996","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0376-8716(99)00152-0","article-title":"Influence of the N-1 alkyl chain length of cannabimimetic indoles upon CB1 and CB2 receptor binding","volume":"60","author":"Aung","year":"2000","journal-title":"Drug Alcohol Depend."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.bmc.2004.09.050","article-title":"Structure-activity relationships for 1-alkyl-3-(1-naphthoyl)indoles at the cannabinoid CB(1) and CB(2) receptors: Steric and electronic effects of naphthoyl substituents. New highly selective CB(2) receptor agonists","volume":"13","author":"Huffman","year":"2005","journal-title":"Bioorg. Med. Chem."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1016\/j.bmc.2012.01.038","article-title":"Synthesis and pharmacology of 1-alkyl-3-(1-naphthoyl)indoles: Steric and electronic effects of 4- and 8-halogenated naphthoyl substituents","volume":"20","author":"Wiley","year":"2012","journal-title":"Bioorg. Med. Chem."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1016\/0960-894X(96)00426-X","article-title":"New class of potent ligands for the human peripheral cannabinoid receptor","volume":"6","author":"Gallant","year":"1996","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.neuropharm.2004.12.008","article-title":"Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy","volume":"48","author":"Valenzano","year":"2005","journal-title":"Neuropharmacology"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0304-3959(01)00454-7","article-title":"CB1 and CB2 cannabinoid receptors are implicated in inflammatory pain","volume":"96","author":"Clayton","year":"2002","journal-title":"Pain"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1111\/j.1460-9568.2006.04684.x","article-title":"CB2 receptor-mediated antihyperalgesia: Possible direct involvement of neural mechanisms","volume":"23","author":"Beltramo","year":"2006","journal-title":"Eur. J. Neurosci."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"10529","DOI":"10.1073\/pnas.1834309100","article-title":"Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: Pain inhibition by receptors not present in the CNS","volume":"100","author":"Ibrahim","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/sj.bjp.0707303","article-title":"Species-specific in vitro pharmacological effects of the cannabinoid receptor 2 (CB2) selective ligand AM1241 and its resolved enantiomers","volume":"151","author":"Bingham","year":"2007","journal-title":"Br. J. Pharmacol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/j.1476-5381.2009.00154.x","article-title":"Constitutive activity of cannabinoid-2 (CB2) receptors plays an essential role in the protean agonism of (+)AM1241 and L768242","volume":"158","author":"Mancini","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1097\/00000542-200310000-00031","article-title":"Inhibition of Inflammatory Hyperalgesia by Activation of Peripheral CB2Cannabinoid Receptors","volume":"99","author":"Quartilho","year":"2003","journal-title":"Anesthesiology"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1016\/S0960-894X(02)00466-3","article-title":"C-3 Amido-Indole cannabinoid receptor modulators","volume":"12","author":"Hynes","year":"2002","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_70","unstructured":"Dart, M., Frost, J., Tietje, K., Daza, A., Grayson, G., Fan, Y., Mukherjee, S., Garrison, T.R., Yao, B., and Meyer, M. (2006). 1-Alkyl-3-ketoindoles: Identification and in vitro characterization of a series of potent cannabinoid ligands. Symposium on the Cannabinoids, International Cannabinoid Research Society."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/0024-3205(95)00175-6","article-title":"AM630, a competitive cannabinoid receptor antagonist","volume":"56","author":"Pertwee","year":"1995","journal-title":"Life Sci."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1111\/j.1476-5381.1996.tb15663.x","article-title":"Further evidence for the presence of cannabinoid CB1 receptors in guinea-pig small intestine","volume":"118","author":"Pertwee","year":"1996","journal-title":"Br. J. Pharmacol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1016\/S0014-2999(97)00047-2","article-title":"AM630 antagonism of cannabinoid-stimulated [35S] GTP gamma S binding in the mouse brain","volume":"321","author":"Hosohata","year":"1997","journal-title":"Eur. J. Pharmacol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"PL115","DOI":"10.1016\/S0024-3205(97)00596-1","article-title":"AM630 is a competitive cannabinoid receptor antagonist in the guinea pig brain","volume":"61","author":"Hosohata","year":"1997","journal-title":"Life Sci."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"PL109","DOI":"10.1016\/S0024-3205(97)01187-9","article-title":"AM630 is an inverse agonist at the human cannabinoid CB1 receptor","volume":"62","author":"Landsman","year":"1998","journal-title":"Life Sci."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/sj.bjp.0702351","article-title":"Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656 and AM630","volume":"126","author":"Ross","year":"1999","journal-title":"Br. J. Pharmacol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1124\/jpet.116.232561","article-title":"Functional Selectivity of CB2 Cannabinoid Receptor Ligands at a Canonical and Noncanonical Pathway","volume":"358","author":"Dhopeshwarkar","year":"2016","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0022-3565(24)35174-2","article-title":"The third transmembrane helix of the cannabinoid receptor plays a role in the selectivity of aminoalkylindoles for CB2, peripheral cannabinoid receptor","volume":"291","author":"Chin","year":"1999","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S0026-895X(24)12187-6","article-title":"Role of a conserved lysine residue in the peripheral cannabinoid receptor (CB2): Evidence for subtype specificity","volume":"55","author":"Tao","year":"1999","journal-title":"Mol. Pharmacol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/S0014-5793(00)01094-2","article-title":"Role of the highly conserved Asp-Arg-Tyr motif in signal transduction of the CB2 cannabinoid receptor","volume":"466","author":"Rhee","year":"2000","journal-title":"FEBS Lett."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/S0006-2952(03)00005-4","article-title":"Effects of D3.49A, R3.50A, and A6.34E mutations on ligand binding and activation of the cannabinoid-2 (CB2) receptor","volume":"65","author":"Feng","year":"2003","journal-title":"Biochem. Pharmacol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1046\/j.1471-4159.2000.0752485.x","article-title":"Functional role of tryptophan residues in the fourth transmembrane domain of the CB(2) cannabinoid receptor","volume":"75","author":"Rhee","year":"2000","journal-title":"J. Neurochem."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1124\/mol.111.074013","article-title":"Functional Selectivity in CB2 Cannabinoid Receptor Signaling and Regulation: Implications for the Therapeutic Potential of CB2 Ligands","volume":"81","author":"Atwood","year":"2012","journal-title":"Mol. Pharmacol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1023\/A:1026306804802","article-title":"Binding of aminoalkylindoles to noncannabinoid binding sites in NG108-15 cells","volume":"17","author":"Stark","year":"1997","journal-title":"Cell. Mol. Neurobiol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/0304-3940(96)12792-0","article-title":"Determination of the cannabinoid receptors in mouse x rat hybridoma NG108-15 cells and rat GH4C1 cells","volume":"212","author":"Ho","year":"1996","journal-title":"Neurosci. Lett."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1111\/j.1471-4159.1986.tb08515.x","article-title":"An Assessment of the Role of Opioid Receptors in the Response to Cannabimimetic Drugs","volume":"46","author":"Devane","year":"1986","journal-title":"J. Neurochem."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1124\/mol.60.1.155","article-title":"Evidence for a New G Protein-Coupled Cannabinoid Receptor in Mouse Brain","volume":"60","author":"Breivogel","year":"2001","journal-title":"Mol. Pharmacol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1006\/bbrc.2002.6635","article-title":"Novel, Not Adenylyl Cyclase-Coupled Cannabinoid Binding Site in Cerebellum of Mice","volume":"292","author":"Monory","year":"2002","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0306-4522(01)00287-1","article-title":"Novel cannabinoid-sensitive receptor mediates inhibition of glutamatergic synaptic transmission in the hippocampus","volume":"106","author":"Ledent","year":"2001","journal-title":"Neuroscience"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.neuropharm.2007.07.003","article-title":"CB1 receptor-dependent and -independent inhibition of excitatory postsynaptic currents in the hippocampus by WIN 55212-2","volume":"54","author":"Ledent","year":"2008","journal-title":"Neuropharmacology"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.brainres.2008.01.011","article-title":"Inhibition of spontaneous neurotransmission in the nucleus of solitary tract of the rat by the cannabinoid agonist WIN 55212-2 is not via CB1 or CB2 receptors","volume":"1200","author":"Almado","year":"2008","journal-title":"Brain Res."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1002\/glia.20983","article-title":"Cannabinoid and cannabinoid-like receptors in microglia, astrocytes, and astrocytomas","volume":"58","author":"Stella","year":"2010","journal-title":"Glia"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1002\/glia.22845","article-title":"Alkylindole-sensitive receptors modulate microglial cell migration and proliferation","volume":"63","author":"Fung","year":"2015","journal-title":"Glia"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.phrs.2016.10.025","article-title":"Novel indole-based compounds that differentiate alkylindole-sensitive receptors from cannabinoid receptors and microtubules: Characterization of their activity on glioma cell migration","volume":"115","author":"Fung","year":"2017","journal-title":"Pharmacol. Res."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1158\/1535-7163.MCT-15-0800","article-title":"ST-11: A New Brain-Penetrant Microtubule-Destabilizing Agent with Therapeutic Potential for Glioblastoma Multiforme","volume":"15","author":"Cherry","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1089\/can.2017.0036","article-title":"An Update on Non-CB(1), Non-CB(2) Cannabinoid Related G-Protein-Coupled Receptors","volume":"2","author":"Morales","year":"2017","journal-title":"Cannabis Cannabinoid Res."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1021\/ja01182a067","article-title":"Tetrahydrocannabinol homologs. XVII","volume":"70","author":"Adams","year":"1948","journal-title":"J. Am. Chem. Soc."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1021\/ja01255a061","article-title":"Tetrahydrocannabinol homologs with marihuana activity. XIII","volume":"64","author":"Adams","year":"1942","journal-title":"J. Am. Chem. Soc."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1021\/ja01182a068","article-title":"Tetrahydrocannabinol Homologs with Doubly Branched Alkyl Groups in the 3-Position. XVIII1","volume":"70","author":"Adams","year":"1948","journal-title":"J. Am. Chem. Soc."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s12210-020-00956-0","article-title":"The early history of cannabinoid research","volume":"31","author":"Appendino","year":"2020","journal-title":"Rend. Fis. Acc. Lincei"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.2307\/4585762","article-title":"Studies on Marihuana and Pyrahexyl Compound","volume":"61","author":"Williams","year":"1946","journal-title":"Public Health Rep."},{"key":"ref_102","unstructured":"Ketchum, J.S. (2006). Chemical Warfare Secrets Almost Forgotten: A Personal Story of Medical Testing of Army Volunteers with Incapacitating Chemical Agents during the Cold War (1955\u20131975), Chembooks."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/nyas.14349","article-title":"Designer drugs: A medicinal chemistry perspective (II)","volume":"1489","author":"Carroll","year":"2021","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1080\/02791072.2016.1229877","article-title":"The Presence of New Psychoactive Substances in a Tor Network Marketplace Environment","volume":"48","author":"Dolliver","year":"2016","journal-title":"J. Psychoact. Drugs"},{"key":"ref_105","unstructured":"European Monitoring Centre for Drugs and Drug Addiction (2021). European Drug Report 2021: Trends and Developments 2021, Publications Office of the European Union."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1093\/jat\/bks025","article-title":"Use of SPME-HS-GC-MS for the Analysis of Herbal Products Containing Synthetic Cannabinoids","volume":"36","author":"Cox","year":"2012","journal-title":"J. Anal. Toxicol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1093\/jat\/bkr018","article-title":"Purity of Synthetic Cannabinoids Sold Online for Recreational Use","volume":"36","author":"Ginsburg","year":"2012","journal-title":"J. Anal. Toxicol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/dta.2673","article-title":"Profiling of synthesis-related impurities of the synthetic cannabinoid Cumyl-5F-PINACA in seized samples of e-liquids via multivariate analysis of UHPLC-MS(n) data","volume":"12","author":"Matzenbach","year":"2020","journal-title":"Drug Test Anal."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1111\/1556-4029.13367","article-title":"Identification of Eight Synthetic Cannabinoids, Including 5F-AKB48 in Seized Herbal Products Using DART-TOF-MS and LC-QTOF-MS as Nontargeted Screening Methods","volume":"62","author":"Moore","year":"2017","journal-title":"J. Forensic Sci."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1002\/dta.1456","article-title":"UR-144 in products sold via the Internet: Identification of related compounds and characterization of pyrolysis products","volume":"5","author":"Kavanagh","year":"2013","journal-title":"Drug Test Anal."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"5574","DOI":"10.1021\/ac300509h","article-title":"Analysis of Synthetic Cannabinoids Using High-Resolution Mass Spectrometry and Mass Defect Filtering: Implications for Nontargeted Screening of Designer Drugs","volume":"84","author":"Grabenauer","year":"2012","journal-title":"Anal. Chem."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.lfs.2012.10.031","article-title":"Analytical surveillance of emerging drugs of abuse and drug formulations","volume":"92","author":"Thomas","year":"2013","journal-title":"Life Sci."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.neuropharm.2016.07.016","article-title":"Evaluation of first generation synthetic cannabinoids on binding at non-cannabinoid receptors and in a battery of in vivo assays in mice","volume":"110","author":"Wiley","year":"2016","journal-title":"Neuropharmacology"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.neuropharm.2013.07.022","article-title":"Cannabinoids in disguise: \u03949-Tetrahydrocannabinol-like effects of tetramethylcyclopropyl ketone indoles","volume":"75","author":"Wiley","year":"2013","journal-title":"Neuropharmacology"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/7854_2016_17","article-title":"Combination Chemistry: Structure\u2013Activity Relationships of Novel Psychoactive Cannabinoids","volume":"32","author":"Wiley","year":"2017","journal-title":"Curr. Top. Behav. Neurosci."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.lfs.2013.09.011","article-title":"Moving around the molecule: Relationship between chemical structure and in vivo activity of synthetic cannabinoids","volume":"97","author":"Wiley","year":"2014","journal-title":"Life Sci."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.tips.2016.12.003","article-title":"Synthetic Pot: Not Your Grandfather\u2019s Marijuana","volume":"38","author":"Ford","year":"2017","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/164_2018_143","article-title":"The Chemistry and Pharmacology of Synthetic Cannabinoid Receptor Agonists as New Psychoactive Substances: Origins","volume":"252","author":"Banister","year":"2018","journal-title":"Handb. Exp. Pharmacol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/164_2018_144","article-title":"The Chemistry and Pharmacology of Synthetic Cannabinoid Receptor Agonist New Psychoactive Substances: Evolution","volume":"252","author":"Banister","year":"2018","journal-title":"Handb. Exp. Pharmacol."},{"key":"ref_120","unstructured":"Thomas, B.F., Daw, R.C., Pande, P.G., Cox, A.O., Kovach, A.L., Davis, K.H., and Grabenauer, M. (2013, January 21\u201326). Analysis of Smoke Condensate From Combustion of Synthetic Cannabinoids in Herbal Products. Proceedings of the 23rd Annual International Cannabinoid Research Society Symposium on the Cannabinoids, Vancouver, BC, Canada."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1016\/j.drugalcdep.2014.02.142","article-title":"Pyrolysis studies of synthetic cannabinoids in herbal products","volume":"140","author":"Daw","year":"2014","journal-title":"Drug Alcohol Depend."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s11419-013-0221-6","article-title":"Thermal degradation of a new synthetic cannabinoid QUPIC during analysis by gas chromatography\u2013mass spectrometry","volume":"32","author":"Tsujikawa","year":"2014","journal-title":"Forensic Toxicol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1124\/jpet.116.238717","article-title":"Thermolytic Degradation of Synthetic Cannabinoids: Chemical Exposures and Pharmacological Consequences","volume":"361","author":"Thomas","year":"2017","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_124","first-page":"1","article-title":"Synthetic cannabinoids are recurring chemical threats","volume":"26","author":"Thomas","year":"2015","journal-title":"Cayman Curr."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1124\/jpet.117.246983","article-title":"Molecular and Behavioral Pharmacological Characterization of Abused Synthetic Cannabinoids MMB- and MDMB-FUBINACA, MN-18, NNEI, CUMYL-PICA, and 5-Fluoro-CUMYL-PICA","volume":"365","author":"Gamage","year":"2018","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.bbrc.2018.03.028","article-title":"Altered metabolism of synthetic cannabinoid JWH-018 by human cytochrome P450 2C9 and variants","volume":"498","author":"Patton","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s11419-018-0430-0","article-title":"Toxic by design? Formation of thermal degradants and cyanide from carboxamide-type synthetic cannabinoids CUMYL-PICA, 5F-CUMYL-PICA, AMB-FUBINACA, MDMB-FUBINACA, NNEI, and MN-18 during exposure to high temperatures","volume":"37","author":"Kevin","year":"2019","journal-title":"Forensic Toxicol."},{"key":"ref_128","first-page":"265","article-title":"Gas and Liquid Chromatography-Mass Spectrometry Detection of the Urinary Metabolites of UR-144 and Its Major Pyrolysis Product","volume":"37","author":"Grigoryev","year":"2013","journal-title":"J. Anal. Toxicol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s11920-016-0694-1","article-title":"Adverse Effects of Synthetic Cannabinoids: Management of Acute Toxicity and Withdrawal","volume":"18","author":"Cooper","year":"2016","journal-title":"Curr. Psychiatry Rep."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/nrcardio.2017.130","article-title":"Cardiovascular effects of marijuana and synthetic cannabinoids: The good, the bad, and the ugly","volume":"15","author":"Pacher","year":"2018","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1177\/1039856218822749","article-title":"Synthetic cannabinoid use disorder: An update for general psychiatrists","volume":"27","author":"Grigg","year":"2019","journal-title":"Australas. Psychiatry"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"100460","DOI":"10.1016\/j.eclinm.2020.100460","article-title":"An outbreak of deaths associated with AMB-FUBINACA in Auckland NZ","volume":"25","author":"Morrow","year":"2020","journal-title":"EClinicalMedicine"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s12024-020-00334-0","article-title":"Emergence of Cumyl-PEGACLONE-related fatalities in the Northern Territory of Australia","volume":"17","author":"Tiemensma","year":"2021","journal-title":"Forensic Sci. Med. Pathol."},{"key":"ref_134","doi-asserted-by":"crossref","unstructured":"Ralphs, R., Williams, L., Askew, R., and Norton, A. (2016). Adding Spice to the Porridge: The development of a synthetic cannabinoid market in an English prison. CrimRxiv.","DOI":"10.21428\/cb6ab371.828f7130"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1515\/cclm-2014-0612","article-title":"Urinary prevalence, metabolite detection rates, temporal patterns and evaluation of suitable LC-MS\/MS targets to document synthetic cannabinoid intake in US military urine specimens","volume":"53","author":"Wohlfarth","year":"2015","journal-title":"Clin. Chem. Lab. Med."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"4350","DOI":"10.1021\/acschemneuro.9b00429","article-title":"Do Toxic Synthetic Cannabinoid Receptor Agonists Have Signature in Vitro Activity Profiles? A Case Study of AMB-FUBINACA","volume":"10","author":"Finlay","year":"2019","journal-title":"ACS Chem. Neurosci."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"e00566","DOI":"10.1002\/prp2.566","article-title":"Differential activation of G protein-mediated signaling by synthetic cannabinoid receptor agonists","volume":"8","author":"Sachdev","year":"2020","journal-title":"Pharmacol. Res. Perspect."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.cell.2018.11.040","article-title":"Structure of a Signaling Cannabinoid Receptor 1-G Protein Complex","volume":"176","author":"Kumar","year":"2019","journal-title":"Cell"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.cell.2020.01.007","article-title":"Cryo-EM Structure of the Human Cannabinoid Receptor CB2-Gi Signaling Complex","volume":"180","author":"Xing","year":"2020","journal-title":"Cell"}],"updated-by":[{"DOI":"10.3390\/molecules29153456","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,10,14]],"date-time":"2021-10-14T00:00:00Z","timestamp":1634169600000}}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/26\/20\/6190\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,3]],"date-time":"2025-08-03T22:12:43Z","timestamp":1754259163000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/26\/20\/6190"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,14]]},"references-count":139,"journal-issue":{"issue":"20","published-online":{"date-parts":[[2021,10]]}},"alternative-id":["molecules26206190"],"URL":"https:\/\/doi.org\/10.3390\/molecules26206190","relation":{"correction":[{"id-type":"doi","id":"10.3390\/molecules29153456","asserted-by":"object"}]},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,14]]}}}